Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by general360on May 28, 2021 5:23pm
211 Views
Post# 33290665

RE:RE:RE:RE:NASH?

RE:RE:RE:RE:NASH?
aha, guilty as charged,thank you Golf / sir!  u never can tell these days, got my first email from someone named Steve who also included pronouns in the signature block: "he/him".  kinda strange, i looked up his linkedin profile and he's a regular looking dude.  then i got a 2nd email from someone else at that company. weird that ppl have to announce pronouns these days, life is complicated enuf already, and anyways....

thanks a lot for the list!  that NASH thing i was talking about was from barrons and said something along the lines of this failure really shaking things up.  i'm interpreting another look at another approach, like ole 208.  all these artifcles u posted w/ links to 35B this that the other.... seriously, this sounds like a wonder drug and it doesnt take much to think ppl dont want this on the market so maybe we're facing an uphill battle fighting against BP... shouldnt this be like a 100+ BILLION market cap co w/ all these potential effects?  staggering when u really think of it...

split ballin of course, just trying to keep the dream alive, it seems to have died on the vine a while ago...

other miscellaneous musings:

cannacord is alllllll over the buy side of things for like the past week/2+.... in my experience cannacrap= exterme volatilty... we've been range bound for so long, every single +~4% seems to get squashed, again.  i'm expecting extreme volatility coming w/ them involved.  my limited experience w/ them is in mining stox and i have historically been slaughtered and i see them moving the price all over the place. we'll see..
thanks for the list again...

have a great weekend, maybe we'll see an NR monday morning that 1st patient is dosed.  just saw polar one over @ agora said dosing starts today in Canada.  if that's true, id expect an NR from the company.  and i'd also expect our first patient to walk out of the hospital Monday morning, head straight to the 'puter and start buying this hand over fist....

'cmon big volume, +++$, low volatility and NO MORE WHAMMIES!!!!

<< Previous
Bullboard Posts
Next >>